Thomas Marjot1, Gustav Buescher2, Marcial Sebode2, Eleanor Barnes3, A Sidney Barritt4, Matthew J Armstrong5, Luke Baldelli6, James Kennedy3, Carolyn Mercer3, Ann-Kathrin Ozga7, Christian Casar2, Christoph Schramm8, Andrew M Moon4, Gwilym J Webb9, Ansgar W Lohse10. 1. Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK. Electronic address: thomas.marjot@ndm.ox.ac.uk. 2. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany. 3. Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK. 4. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA. 5. Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK. 6. Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. 7. Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 8. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany; Martin Zeitz Centre for Rare Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. 9. Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK. 10. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany. Electronic address: alohse@uke.de.
Abstract
BACKGROUND & AIMS: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). METHODS: Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). RESULTS: Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) patients with AIH were taking ≥1 immunosuppressive drug. There were no differences in rates of major outcomes between patients with AIH and non-AIH CLD, including hospitalization (76% vs. 85%; p = 0.06), intensive care unit admission (29% vs. 23%; p = 0.240), and death (23% vs. 20%; p = 0.643). Factors associated with death within the AIH cohort included age (odds ratio [OR] 2.16/10 years; 1.07-3.81), and Child-Pugh class B (OR 42.48; 4.40-409.53), and C (OR 69.30; 2.83-1694.50) cirrhosis, but not use of immunosuppression. Propensity score matched (PSM) analysis comparing patients with AIH with non-AIH CLD demonstrated no increased risk of adverse outcomes including death (+3.2%; -9.2%-15.7%). PSM analysis of patients with AIH vs. non-CLD (n = 769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6-31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%-15.6%). CONCLUSION: Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease. LAY SUMMARY: Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.
BACKGROUND & AIMS:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). METHODS: Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). RESULTS: Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) patients with AIH were taking ≥1 immunosuppressive drug. There were no differences in rates of major outcomes between patients with AIH and non-AIH CLD, including hospitalization (76% vs. 85%; p = 0.06), intensive care unit admission (29% vs. 23%; p = 0.240), and death (23% vs. 20%; p = 0.643). Factors associated with death within the AIH cohort included age (odds ratio [OR] 2.16/10 years; 1.07-3.81), and Child-Pugh class B (OR 42.48; 4.40-409.53), and C (OR 69.30; 2.83-1694.50) cirrhosis, but not use of immunosuppression. Propensity score matched (PSM) analysis comparing patients with AIH with non-AIH CLD demonstrated no increased risk of adverse outcomes including death (+3.2%; -9.2%-15.7%). PSM analysis of patients with AIH vs. non-CLD (n = 769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6-31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%-15.6%). CONCLUSION:Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease. LAY SUMMARY: Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.
Authors: Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-29 Impact factor: 19.103
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Elizabeth J Williamson; Alex J Walker; Krishnan Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Y S Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen J W Evans; Liam Smeeth; Ben Goldacre Journal: Nature Date: 2020-07-08 Impact factor: 49.962
Authors: Gwilym J Webb; Thomas Marjot; Jonathan A Cook; Costica Aloman; Matthew J Armstrong; Erica J Brenner; Maria-Andreea Catana; Tamsin Cargill; Renumathy Dhanasekaran; Ignacio García-Juárez; Hannes Hagström; James M Kennedy; Aileen Marshall; Steven Masson; Carolyn J Mercer; Ponni V Perumalswami; Isaac Ruiz; Sarang Thaker; Nneka N Ufere; Eleanor Barnes; Alfred S Barritt; Andrew M Moon Journal: Lancet Gastroenterol Hepatol Date: 2020-08-28
Authors: Jean-Frederic Colombel; Michael D Kappelman; Ryan C Ungaro; Erica J Brenner; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Flávio Steinwurz; Fox E Underwood; Xian Zhang Journal: Gut Date: 2020-10-20 Impact factor: 31.793
Authors: Rommel Ravanan; Chris J Callaghan; Lisa Mumford; Ines Ushiro-Lumb; Douglas Thorburn; John Casey; Peter Friend; Jayan Parameshwar; Ian Currie; Lisa Burnapp; Richard Baker; Jan Dudley; Gabriel C Oniscu; Marius Berman; John Asher; Dan Harvey; Alex Manara; Derek Manas; Dale Gardiner; John L R Forsythe Journal: Am J Transplant Date: 2020-09-16 Impact factor: 9.369
Authors: Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg Journal: J Hepatol Date: 2022-07-20 Impact factor: 30.083